Literature DB >> 24397962

The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren's syndrome: a critical review.

Takayuki Sumida1, Hiroto Tsuboi2, Mana Iizuka2, Tomoya Hirota2, Hiromitsu Asashima2, Isao Matsumoto2.   

Abstract

CD4+ T cells constitute the majority of infiltrating cells in salivary glands and lachrymal glands of patients with Sjögren's syndrome (SS). The pathophysiology of SS involves T cell recognition of antigens through the T cell antigen receptor, which triggers cytokine production and chronic inflammation. The M3 muscarinic acetylcholine receptor (M3R) molecule is expressed in exocrine glands, such as salivary glands and lachrymal glands, and plays an important role in exocrine secretion. Previous studies indicated the presence of M3R reactive T cells in peripheral blood of 40% of patients with SS and autoantibodies against M3R in sera of 9-100% of the same patients. Thus, M3R is considered a candidate receptor for autoantigen recognition by T and B cells. The relationship between B cell epitopes and the function of anti-M3R antibodies has been reported, suggesting the pathogenic role of anti-M3R antibodies in xerostomia commonly seen in SS patients. We generated new experimental mouse model, M3R-induced sialadenitis (MIS), using Rag1(-/-) mice inoculated with splenocytes from M3R(-/-) mice immunized with M3R synthetic peptides. Mice with MIS developed severe SS-like sialadenitis. Cell transfer experiments using M3R(-/-)xIFNγ(-/-) mice and M3R(-/-)xIL-17(-/-) mice showed that IFNγ and IL-17 are key cytokines in the pathogenesis of sialadenitis. These findings indicate the crucial roles of M3R-reactive Th1 and Th17 cells in autoimmune sialadenitis, and suggest that these cells, in addition to anti-M3R antibodies, are potential targets in new treatments for SS.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  M3R; M3R induced sialadenitis; M3R reactive T cells; Sjögren's syndrome; anti-M3R antibodies

Mesh:

Substances:

Year:  2014        PMID: 24397962     DOI: 10.1016/j.jaut.2013.12.012

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  20 in total

1.  M3 muscarinic acetylcholine receptor-reactive Th17 cells in primary Sjögren's syndrome.

Authors:  Saori Abe; Hiroto Tsuboi; Hanae Kudo; Hiromitsu Asashima; Yuko Ono; Fumika Honda; Hiroyuki Takahashi; Mizuki Yagishita; Shinya Hagiwara; Yuya Kondo; Isao Matsumoto; Takayuki Sumida
Journal:  JCI Insight       Date:  2020-08-06

2.  Type 3 muscarinic receptors contribute to intestinal mucosal homeostasis and clearance of Nippostrongylus brasiliensis through induction of TH2 cytokines.

Authors:  Leon P McLean; Allen Smith; Lumei Cheung; Joseph F Urban; Rex Sun; Viktoriya Grinchuk; Neemesh Desai; Aiping Zhao; Jean-Pierre Raufman; Terez Shea-Donohue
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-05-12       Impact factor: 4.052

Review 3.  Studying Sjögren's syndrome in mice: What is the best available model?

Authors:  Ghada Abughanam; Ola M Maria; Simon D Tran
Journal:  J Oral Biol Craniofac Res       Date:  2020-12-08

4.  The Pathobiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Case for Neuroglial Failure.

Authors:  Herbert Renz-Polster; Marie-Eve Tremblay; Dorothee Bienzle; Joachim E Fischer
Journal:  Front Cell Neurosci       Date:  2022-05-09       Impact factor: 6.147

5.  Muscarinic type 3 receptor autoantibodies are associated with anti-SSA/Ro autoantibodies in Sjögren's syndrome.

Authors:  Jian Zuo; Adrienne E G Williams; Yun-Jong Park; Kevin Choi; Annie L Chan; Westley H Reeves; Michael R Bubb; Yun Jong Lee; Kyungpyo Park; Carol M Stewart; Seunghee Cha
Journal:  J Immunol Methods       Date:  2016-07-25       Impact factor: 2.303

Review 6.  Autoimmunity in 2014.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

7.  Reduction of T cell receptor diversity in NOD mice prevents development of type 1 diabetes but not Sjögren's syndrome.

Authors:  Joanna Kern; Robert Drutel; Silvia Leanhart; Marek Bogacz; Rafal Pacholczyk
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

Review 8.  Sjögren's syndrome: still not fully understood disease.

Authors:  Maria Maślińska; Małgorzata Przygodzka; Brygida Kwiatkowska; Katarzyna Sikorska-Siudek
Journal:  Rheumatol Int       Date:  2014-07-02       Impact factor: 2.631

9.  Autoantibodies against the Second Extracellular Loop of M3R Do neither Induce nor Indicate Primary Sjögren's Syndrome.

Authors:  Yan Chen; Junfeng Zheng; Qiaoniang Huang; Fengyuan Deng; Renliang Huang; Wenjie Zhao; Junping Yin; Lina Song; Juan Chen; Xing Gao; Zuguo Liu; Frank Petersen; Xinhua Yu
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

10.  Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks.

Authors:  Hiroto Tsuboi; Isao Matsumoto; Shinya Hagiwara; Tomoya Hirota; Hiroyuki Takahashi; Hiroshi Ebe; Masahiro Yokosawa; Chihiro Hagiya; Hiromitsu Asashima; Chinatsu Takai; Haruka Miki; Naoto Umeda; Yuya Kondo; Hiroshi Ogishima; Takeshi Suzuki; Shintaro Hirata; Kazuyoshi Saito; Yoshiya Tanaka; Yoshiro Horai; Hideki Nakamura; Atsushi Kawakami; Takayuki Sumida
Journal:  Mod Rheumatol       Date:  2014-09-11       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.